Savara to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, will present at the Jefferies London Healthcare Conference from November 16-19, 2021. A pre-recorded, on-demand webcast of the presentation will be available starting November 18 at 3:00 am ET until November 19 at 12:00 pm ET. The replay will be accessible on Savara's Investors page for 90 days post-event. Savara's lead product, molgramostim, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

A pre-recorded, on-demand webcast of Savara’s presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the presentation will be available on the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ for 90 days following the event.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005243/en/

Savara Inc. IR & PR

Anne Erickson

Senior Vice President, Chief of Staff

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

When will Savara Inc. present at the Jefferies London Healthcare Conference?

Savara Inc. will present at the Jefferies London Healthcare Conference from November 16-19, 2021.

What is the URL for the on-demand webcast of Savara's presentation?

The on-demand webcast of Savara's presentation will be available at www.savarapharma.com/investors/events-presentations starting November 18, 2021.

What is molgramostim and its purpose in Savara's development?

Molgramostim is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

How long will the replay of Savara's conference presentation be available?

The replay of Savara's conference presentation will be available for 90 days following the event.

What significant stage is Savara's lead program currently in?

Savara's lead program, molgramostim, is currently in Phase 3 development.